Vol 10, Supp. C (2019)

Date published: 2019-10-02

Table of Contents

open access


The role of brentuximab vedotin in the treatment of patients with refractory/relapsed Hodgkin lymphoma based on two case reports

Monika Chełstowska, Krzysztof Jamroziak, Ewa Lech-Marańda, Krzysztof Warzocha

Case report

DOI: 10.5603/Hem.2019.0024

Long-term response on brentuximab vedotin therapy in patients with Hodgkin lymphoma

Andrzej Pluta, Justyna Gil, Jacek Krzanowski, Sławomir Radwański

Case report

DOI: 10.5603/Hem.2019.0020


Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl